Fig. 2: Drug treatments induced UGT2B17 expression and activity in CLL cell models.
From: UGT2B17 modifies drug response in chronic lymphocytic leukaemia
Quantification of UGT2B17 (left panels) and UGT1A (right panels) mRNAs by RT-qPCR in MEC1 (a), JVM2 (b) and EHEB (c) cells subjected to fludarabine, ibrutinib or idelalisib treatment at specified concentrations. d Drug treatments induced UGT2B17 (left) and UGT1A (right) glucuronidation activity for their probe substrates dihydrotestosterone (DHT) and oestradiol (E2), respectively. e Fludarabine glucuronidation was enhanced following treatment with fludarabine, ibrutinib or idelalisib. f Relative expression levels (×103) of UGT1A and UGT2B17 in leukaemic cell models. G Glucuronide. Student’s T-test; *P < 0.05, **P < 0.01, ***P < 0.001.
